WALTHAM, Mass • 2023-10-02

BostonGene to Present Unique AI-Driven Bioinformatic Solutions at the Festival of Genomics & Biodata

5 min to read

BostonGene, a leading provider of AI-based molecular and immune profiling solutions, announced today that it will participate in and present at the Festival of Genomics & Biodata
WALTHAM, Mass, October 2, 2023

BostonGene, a leading provider of AI-based molecular and immune profiling solutions, announced today that it will participate in and present at the Festival of Genomics & Biodata, the world’s largest genomics & biodata annual meeting that brings together scientists, researchers, clinicians, technology companies, investors and patient organizations to realize the true potential of genomics medicine and related applications, which is being held October 5 - 6, 2023 in Boston, MA at the Boston Convention & Expo Center. BostonGene will also exhibit at booth 17.

BostonGene session details are below:



From Concept to Clinic: Developing unique AI-driven informatics solutions to power cancer discovery

  • Thursday, October 5, 2023 | 9:30 AM ET

  • Speaker: Nathan Fowler, MD, Chief Medical Officer, BostonGene

  • Location: Main stage


In this session, BostonGene will discuss how advances in next-generation sequencing have generated a wealth of unmined genomic data across myriad fields, including oncology. The presentation will cover comprehensive solutions that combine high-complexity bioinformatics, large throughput molecular and genomic CLIA/CAP technologies, and several large-scale databases to support early and late discovery projects.

To learn more or to schedule a meeting with BostonGene during the event, please contact Maria Proia at maria.proia@bostongene.com.

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin O’Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com